A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out how safe and effective an investigational drug
called alefacept (amevive) is for the treatment of moderate to severe erosive mucosal lichen
planus.
Lichen planus is a skin disease that can last a long time and cause significant pain,
itching, and scarring. It can affect the mucous membranes (area inside the mouth and vagina)
and these areas can become erosive (sores can develop). Currently there is no known cure for
this disease.
An investigational drug is one that has not been approved by the United States (US) Food and
Drug Administration (FDA) to treat a particular condition or disease. Alefacept has been
approved to treat psoriasis (a scaly skin rash). A number of reports suggest that lichen
planus develops for some of the same reasons as psoriasis, but alefacept is not yet approved
for the treatment of psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Biogen Brigham and Women's Hospital Stanford University